Gene: KLK10

5655
NES1|PRSSL1
kallikrein related peptidase 10
protein-coding
19q13.41
Ensembl:ENSG00000129451 MIM:602673 Vega:OTTHUMG00000182916 UniprotKB:O43240
NC_000019.10
PubMed
0   ANCO-SNPs
ND
1   
7.616e-1 (AD)  9.860e-1 (ND)   (Frontal_Cortex)
3.635e-1 (AD)  4.014e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PPM1J0.628
RET0.598
EGF0.584
RIT20.575
IFIT10.573
VSIG10L0.566
CMPK20.554
INSM20.537
SLC7A30.536
STARD50.531

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MTRNR2L2-0.346
MYOM1-0.338
ASB4-0.323
YES1-0.317
HIGD1B-0.313
P2RY14-0.31
REST-0.306
FMO3-0.303
MTRNR2L10-0.301
MTRNR2L6-0.301

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of KLK10 mRNA"20453058
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK10 mRNA"27188386
C103303alitretinoinalitretinoin results in increased expression of KLK10 mRNA16800735
C103303alitretinoinalitretinoin results in increased expression of KLK10 protein16800735
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased expression of KLK10 mRNA"25351596
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in decreased expression of KLK10 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of KLK10 mRNA20064835
C006780bisphenol Abisphenol A results in decreased expression of KLK10 mRNA25181051
C584509C646 compoundC646 compound results in increased expression of KLK10 mRNA26191083
D002104CadmiumCadmium results in decreased expression of KLK10 mRNA21120746
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of KLK10 mRNA23640034
D002945Cisplatin[Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA21791302
D002945CisplatinKLK10 protein affects the susceptibility to Cisplatin16217747
D002117CalcitriolCalcitriol results in increased expression of KLK10 mRNA26485663
C118739entinostatentinostat results in increased expression of KLK10 mRNA26272509|2718838
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK10 mRNA"27188386
D004967Estrogens[Estrogens co-treated with Progesterone] results in increased expression of KLK10 mRNA20686372
D004967EstrogensEstrogens results in increased expression of KLK10 mRNA20686372
D004397FonofosFonofos results in increased methylation of KLK10 promoter22847954
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of KLK10 mRNA26752646
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of KLK10 mRNA28001369
D009532NickelNickel results in increased expression of KLK10 mRNA25583101
C029938nickel sulfatenickel sulfate results in increased expression of KLK10 mRNA18651567
C014707nitrosobenzylmethylaminenitrosobenzylmethylamine results in increased expression of KLK10 mRNA17616710
C496932panobinostat[Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA21791302
D010278ParathionParathion results in increased methylation of KLK10 promoter22847954
D052638Particulate MatterParticulate Matter results in increased expression of KLK10 mRNA28341207
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK10 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of KLK10 mRNA26272509
D011374Progesterone[Estrogens co-treated with Progesterone] results in increased expression of KLK10 mRNA20686372
D012906SmokeSmoke results in decreased expression of KLK10 mRNA21095227
C017947sodium arsenitesodium arsenite affects the methylation of KLK10 gene28589171
C016104sodium bichromatesodium bichromate results in decreased expression of KLK10 mRNA22561333
D012969Sodium FluorideSodium Fluoride results in increased expression of KLK10 mRNA27257137
C012568terbufosterbufos results in increased methylation of KLK10 promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of KLK10 mRNA23152189
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of KLK10 mRNA20133372
D014212TretinoinTretinoin results in increased expression of KLK10 mRNA16249480|1680073
D014635Valproic AcidValproic Acid affects the expression of KLK10 mRNA25979313
D000069470Venlafaxine HydrochlorideVenlafaxine Hydrochloride results in decreased expression of KLK10 mRNA16341940
D015032ZincZinc deficiency results in increased expression of KLK10 mRNA19111725
D015032ZincZinc inhibits the reaction [Zinc deficiency results in increased expression of KLK10 mRNA]19111725
C088658zoledronic acidzoledronic acid results in increased expression of KLK10 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004252serine-type endopeptidase activity-IEA-  
GO:0008236serine-type peptidase activity-TAS8764136  
GO ID GO Term Qualifier Evidence PubMed
GO:0006508proteolysis-IEA-  
GO:0007049cell cycle-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-IEA-  
GO:0030141secretory granule-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
18316555A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. (2008 Mar 1)Planque CClin Cancer Res